Due to the potent anti-fibrotic effect and the additionally observed potent antiangiogenic effect other ophthalmic diseases that are linked to TGF-β2 (wet AMD, dry AMD, diabetic retinopathy, proliferative vitreoretinopathy) may also be explored for ISTH0036 development. Here, TGFB2 is linked to CAPN5-related vitreoretinopathy.